Bone Biologics (Bone Biologics) Accounts Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Bone Biologics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Bone Biologics's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Bone Biologics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $3.01.

Bone Biologics Accounts Receivable Historical Data

The historical data trend for Bone Biologics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bone Biologics Accounts Receivable Chart

Bone Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

Bone Biologics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Bone Biologics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Bone Biologics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Bone Biologics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Bone Biologics's accounts receivable are only considered to be worth 75% of book value:

Bone Biologics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(3.228	+	0.75 * 0	+	0.5 * 0	-	0.165
-	0	-	0)	/	1.01649
=	3.01

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Bone Biologics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Bone Biologics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Bone Biologics (Bone Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLG) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803

Website

https://www.bonebiologics.com

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Executives

Deina H Walsh	officer: Chief Financial Officer	175, MAY STREET, EDISON NJ 08837
Jeff Frelick	officer: Chief Operating Officer	1 FOX RUN LANE,, LEXINGTON MA 02420
Knight Insurance Company, Ltd	10 percent owner	4751 WILSHIRE BLVD.,, SUITE 111, LOS ANGELES CA 90010
Siddhesh Rajendra Angle	director	481 MONMOUTH ST, UNIT G,, JERSEY CITY NJ 07302
Erick Lucera	director	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Don Hankey	director, 10 percent owner, officer: Chairman of the Board	4751 WILSHIRE BLVD., SUITE 110, LOS ANGELES CA 90010
Bret Hankey	director	4751 WILSHIRE BLVD. #110, LOS ANGELES CA 90010
Hankey Capital, Llc	10 percent owner	4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Don Hankey Trust	10 percent owner	4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Amir F Heshmatpour	10 percent owner	269 S. BEVERLY DRIVE, STE #1600, BEVERLY HILLS CA 90212
Musculoskeletal Transplant Foundation, Inc.	director	175 MAY STREET, SUITE 300, EDISON NJ 08837
Benjamin Wu	director	2740 LORAIN ROAD, SAN MARINO CA 91108
La Neve Stephen R.	director, officer: CEO and President	106 MCCOOL BLVD, WEST CHESTER PA 19380
George A Oram	director	12 EDGEMONT LANE, BEDMINSTER NJ 07921
Jim Delshad	director	132 S. MAPLE DR., BEVERLY HILLS CA 90212